Select a medication above to begin.
Brilinta
ticagrelor
Black Box Warnings .
Bleeding Risk
significant and sometimes fatal bleeding may occur; contraindicated in pts w/ active bleeding or intracranial hemorrhage hx; do not start in pts undergoing urgent CABG; if possible, manage bleeding without D/C tx; incr. risk of subsequent cardiovascular events if D/C tx
Adult Dosing .
Dosage forms: TAB: 60 mg, 90 mg
acute coronary syndrome
- [90 mg PO bid x12mo, then 60 mg PO bid]
- Start: 180 mg PO x1, then after 6-12h, 90 mg PO bid; Info: give w/ aspirin 75-100 mg PO qd; if PCI, consider giving w/o aspirin; depending on bleeding risk, consider holding tx 3-5 days before surgery or invasive procedure; resume tx w/in 24h postop
cardiovascular event risk reduction
- [60 mg PO bid]
- Info: for pts w/ MI hx; give w/ aspirin 75-100 mg PO qd; depending on bleeding risk, consider holding tx 3-5 days before surgery or invasive procedure; resume tx w/in 24h postop
CAD
- [60 mg PO bid]
- Info: for pts w/o stroke or MI hx; give w/ aspirin 75-100 mg PO qd; depending on bleeding risk, consider holding tx 3-5 days before surgery or invasive procedure; resume tx w/in 24h postop
acute ischemic stroke
- [90 mg PO bid for up to 30 days]
- Start: 180 mg PO x1, then after 6-12h, 90 mg PO bid; Info: for pts w/ NIHSS score 5 or less; give w/ aspirin 300-325 mg PO x1, then 75-100 mg PO qd
TIA
- [90 mg PO bid for up to 30 days]
- Start: 180 mg PO x1, then after 6-12h, 90 mg PO bid; Info: give w/ aspirin 300-325 mg PO x1, then 75-100 mg PO qd
renal dosing
- [see below]
- renal impairment: no adjustment
- HD: no adjustment; no supplement; PD: not defined
hepatic dosing
- [see below]
- mild impairment: no adjustment; moderate impairment: not defined, caution advised; severe impairment: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.